帕金森病患者接受美多芭联合盐酸普拉克索治疗的临床探究

Clinical Study of Parkinson Disease Patients Received Pramipexole Hydrochloride Combined with Madopar Treatment

目的研究帕金森病患者接受美多芭联合盐酸普拉克索治疗的临床疗效。方法选取2014年—2017年来本院治疗帕金森病的患者80例,随机分为两组,对照组使用美多芭片治疗,观察组给予美多芭联合盐酸普乐克治疗。结果使用美多芭片单独作用治疗下的对照组患者在治疗结束后,患者的帕金森病与入院时进行比较没有明显的改善,观察组患者的帕金森病评分情况与对照组进行比较明显较低,治疗效果更为显著(P<0.05)。结论盐酸普拉克联合美多芭片治疗患者,具有较高地安全性。

Objective Study on Parkinson's disease patients with clinical efficacy of pramipexole hydrochloride combined with Madopar treatment. Methods Based on the recent 3 years(2014—2017 years) in our hospital for the treatment of Parkinson's disease patients,the number of 80 cases,the patients were divided into two groups,the use of Madopar tablets in the treatment of one group of patients(control group),the remaining group was given Madopar hydrochloride combined with Bullock G patients(observation group). Results The use of Madopar tablets alone treatment of the patients in the control group after the treatment of Parkinson's disease and hospitalized patients when compared with no obvious improvement,the observation group of patients with Parkinson's disease score compared with control group were significantly lower,the treatment effect is more significant(P<0.05). Conclusion A hydrochloride combined with Madopar tablets in the treatment of patients with high security.